167 related articles for article (PubMed ID: 21864042)
1. Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network.
Kenkre VP; Long WL; Eickhoff JC; Blank JH; McFarland TA; Bottner W; Rezazedeh H; Werndli JE; Bailey HH; Kahl BS
Leuk Lymphoma; 2011 Sep; 52(9):1675-80. PubMed ID: 21864042
[TBL] [Abstract][Full Text] [Related]
2. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.
Kahl BS; Longo WL; Eickhoff JC; Zehnder J; Jones C; Blank J; McFarland T; Bottner W; Rezazedeh H; Werndli J; Bailey HH;
Ann Oncol; 2006 Sep; 17(9):1418-23. PubMed ID: 16766582
[TBL] [Abstract][Full Text] [Related]
3. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.
Chang JE; Peterson C; Choi S; Eickhoff JC; Kim K; Yang DT; Gilbert LA; Rogers ES; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
Br J Haematol; 2011 Oct; 155(2):190-7. PubMed ID: 21848883
[TBL] [Abstract][Full Text] [Related]
4. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).
Chang JE; Li H; Smith MR; Gascoyne RD; Paietta EM; Yang DT; Advani RH; Horning SJ; Kahl BS
Blood; 2014 Mar; 123(11):1665-73. PubMed ID: 24458437
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Geisler CH; Trneny M; Stilgenbauer S; Kaiser F; Doorduijn JK; Salles G; Szymczyk M; Tilly H; Kanz L; Schmidt C; Feugier P; Thieblemont C; Zijlstra JM; Ribrag V; Klapper W; Pott C; Unterhalt M; Dreyling MH
J Clin Oncol; 2020 Jan; 38(3):248-256. PubMed ID: 31804876
[TBL] [Abstract][Full Text] [Related]
7. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
Fayad L; Thomas D; Romaguera J
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Romaguera JE; Wang M; Feng L; Fayad LE; Hagemeister F; McLaughlin P; Rodriguez MA; Fanale M; Orlowski R; Kwak LW; Neelapu S; Oki Y; Pro B; Younes A; Samaniego F; Fowler N; Hartig K; Valentinetti M; Smith J; Ford P; Naig A; Medeiros LJ; Kantarjian HM; Goy A
Cancer; 2018 Jun; 124(12):2561-2569. PubMed ID: 29723393
[TBL] [Abstract][Full Text] [Related]
9. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group.
Räty R; Honkanen T; Jantunen E; Jyrkkiö S; Karjalainen-Lindsberg ML; Kuittinen O; Lehto M; Mikkola M; Poikonen E; Rauhala A; Rimpiläinen J; Räsänen A; Siitonen S; Suominen M; Vapaatalo M; Elonen E
Leuk Lymphoma; 2012 Oct; 53(10):1920-8. PubMed ID: 22397313
[TBL] [Abstract][Full Text] [Related]
10. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
11. VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
Chang JE; Carmichael LL; Kim K; Peterson C; Yang DT; Traynor AM; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e61-e67. PubMed ID: 29191715
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW
Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
[TBL] [Abstract][Full Text] [Related]
14. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
[TBL] [Abstract][Full Text] [Related]
15. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
Martin P; Chadburn A; Christos P; Furman R; Ruan J; Joyce MA; Fusco E; Glynn P; Elstrom R; Niesvizky R; Feldman EJ; Shore TB; Schuster MW; Ely S; Knowles DM; Chen-Kiang S; Coleman M; Leonard JP
Ann Oncol; 2008 Jul; 19(7):1327-1330. PubMed ID: 18349031
[TBL] [Abstract][Full Text] [Related]
16. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
Houot R; Le Gouill S; Ojeda Uribe M; Mounier C; Courby S; Dartigeas C; Bouabdallah K; Alexis Vigier M; Moles MP; Tournilhac O; Arakelyan N; Rodon P; El Yamani A; Sutton L; Fornecker L; Assouline D; Harousseau JL; Maisonneuve H; Caulet-Maugendre S; Gressin R;
Ann Oncol; 2012 Jun; 23(6):1555-61. PubMed ID: 22012966
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.
Smith MR; Li H; Gordon L; Gascoyne RD; Paietta E; Forero-Torres A; Kahl BS; Advani R; Hong F; Horning SJ
J Clin Oncol; 2012 Sep; 30(25):3119-26. PubMed ID: 22851557
[TBL] [Abstract][Full Text] [Related]
18. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.
Mangel J; Leitch HA; Connors JM; Buckstein R; Imrie K; Spaner D; Crump M; Pennell N; Boudreau A; Berinstein NL
Ann Oncol; 2004 Feb; 15(2):283-90. PubMed ID: 14760123
[TBL] [Abstract][Full Text] [Related]
19. Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue.
Salhotra A; Shan Y; Tsai NC; Sanchez JF; Aldoss I; Ali H; Paris T; Spielberger R; Cao TM; Nademanee A; Forman SJ; Chen R
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1264-1268. PubMed ID: 28434928
[TBL] [Abstract][Full Text] [Related]
20. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
Howard OM; Gribben JG; Neuberg DS; Grossbard M; Poor C; Janicek MJ; Shipp MA
J Clin Oncol; 2002 Mar; 20(5):1288-94. PubMed ID: 11870171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
